BR112022000315A2 - Telmisartana para o tratamento da doença renal crônica em cães - Google Patents

Telmisartana para o tratamento da doença renal crônica em cães

Info

Publication number
BR112022000315A2
BR112022000315A2 BR112022000315A BR112022000315A BR112022000315A2 BR 112022000315 A2 BR112022000315 A2 BR 112022000315A2 BR 112022000315 A BR112022000315 A BR 112022000315A BR 112022000315 A BR112022000315 A BR 112022000315A BR 112022000315 A2 BR112022000315 A2 BR 112022000315A2
Authority
BR
Brazil
Prior art keywords
telmisartan
treatment
dogs
kidney disease
chronic kidney
Prior art date
Application number
BR112022000315A
Other languages
English (en)
Inventor
Erickson Coleman Amanda
Michelle Traas Anne
Natália Ferreira De Moura Lourenço Bianca
Elizabeth Creevy Kate
Alan Brown Scott
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Univ Georgia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh, Univ Georgia filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of BR112022000315A2 publication Critical patent/BR112022000315A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

telmisartana para o tratamento da doença renal crônica em cães. a presente invenção se refere a telmisartana ou um sal farmaceuticamente aceitável do mesmo como um fármaco para o tratamento de níveis elevados de proteína urinária para creatinina (upc) em cães, em que a quantidade terapeuticamente eficaz de telmisartana é administrada em uma quantidade de dosagem diária que é variada ao longo de um período de tratamento.
BR112022000315A 2019-07-09 2020-04-30 Telmisartana para o tratamento da doença renal crônica em cães BR112022000315A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962871752P 2019-07-09 2019-07-09
PCT/US2020/030579 WO2021006941A1 (en) 2019-07-09 2020-04-30 Telmisartan for the treatment of chronic kidney disease in dogs

Publications (1)

Publication Number Publication Date
BR112022000315A2 true BR112022000315A2 (pt) 2022-02-22

Family

ID=70775531

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000315A BR112022000315A2 (pt) 2019-07-09 2020-04-30 Telmisartana para o tratamento da doença renal crônica em cães

Country Status (11)

Country Link
US (1) US20220218671A1 (pt)
EP (1) EP3996705A1 (pt)
JP (1) JP2022540074A (pt)
KR (1) KR20220054291A (pt)
CN (1) CN114450004A (pt)
AU (1) AU2020311280A1 (pt)
BR (1) BR112022000315A2 (pt)
CA (1) CA3142876A1 (pt)
MX (1) MX2022000429A (pt)
TW (1) TW202116305A (pt)
WO (1) WO2021006941A1 (pt)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200026975A (ko) 2017-07-07 2020-03-11 베링거잉겔하임베트메디카게엠베하 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제

Also Published As

Publication number Publication date
US20220218671A1 (en) 2022-07-14
EP3996705A1 (en) 2022-05-18
JP2022540074A (ja) 2022-09-14
CN114450004A (zh) 2022-05-06
MX2022000429A (es) 2022-04-25
CA3142876A1 (en) 2021-01-14
AU2020311280A1 (en) 2022-02-24
WO2021006941A1 (en) 2021-01-14
KR20220054291A (ko) 2022-05-02
TW202116305A (zh) 2021-05-01

Similar Documents

Publication Publication Date Title
BR112017014067A2 (pt) composição para tratar doenças relacionadas a il-6
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
DOP2015000043A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes
CO6480950A2 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
BR112013006953A2 (pt) composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
ECSP12012020A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
EA201071244A1 (ru) Новые терапевтические подходы в лечении болезни альцгеймера и обусловленных ею расстройств посредством модуляции ангиогенеза
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
NZ714963A (en) Compositions and methods for treating anemia
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
NZ602029A (en) Use of meloxicam for the long-term treatment of kidney disorders in cats
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
BR112014017985A8 (pt) Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
BR112015019919A2 (pt) compostos bicíclicos
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
BR112022000315A2 (pt) Telmisartana para o tratamento da doença renal crônica em cães
HRP20201233T1 (hr) Spoj izveden od pirazolina i njegova primjena u tjednom doznom režimu protiv upale i bola porijeklom od degenerativnog oboljenja zgloba kod sisavaca
BR112015012497A2 (pt) combinações farmacêuticas
WO2015051135A3 (en) Organic compositions to treat hepcidin-related diseases
BR112022000398A2 (pt) Telmisartana para o tratamento da hipertensão em cães
BR112018015483A2 (pt) formulações farmacêuticas sólidas estáveis que contêm 2-(2-nitro-4-trifluorometil-benzoil)-1,3 -ciclo-hexanodiona